IMPROVED BENEFIT RISK RATIO OF HIGHER-DOSE METOCLOPRAMIDE THERAPY DURING CISPLATIN-INDUCED EMESIS

被引：16

作者：

SALLER, R

HELLENBRECHT, D

HELLSTERN, A

HESS, H

机构：

[1] UNIV FRANKFURT CLIN,CTR INTERNAL MED,FRANKFURT,FED REP GER

[2] UNIV FRANKFURT CLIN,CTR PHARMACOL,FRANKFURT,FED REP GER

来源：

EUROPEAN JOURNAL OF CLINICAL PHARMACOLOGY | 1985年 / 29卷 / 03期

关键词：

D O I：

10.1007/BF00544086

中图分类号：

R9 [药学];

学科分类号：

1007 ;

摘要：

引用

页码：311 / 312

页数：2

共 5 条

[1] METOCLOPRAMIDE - PHARMACOLOGY AND CLINICAL-APPLICATION [J].

ALBIBI, R ;

MCCALLUM, RW .

ANNALS OF INTERNAL MEDICINE, 1983, 98 (01) :86-95

[2]

ALLAN SG, 1984, LANCET, V1, P283

[3] METOCLOPRAMIDE - A REVIEW OF ANTI-EMETIC TRIALS [J].

GRALLA, RJ .

DRUGS, 1983, 25 :63-73

[4] OPTIMIZING METOCLOPRAMIDE CONTROL OF CISPLATIN-INDUCED EMESIS [J].

MEYER, BR ;

LEWIN, M ;

DRAYER, DE ;

PASMANTIER, M ;

LONSKI, L ;

REIDENBERG, MM .

ANNALS OF INTERNAL MEDICINE, 1984, 100 (03) :393-395

[5] METOCLOPRAMIDE KINETICS AT HIGH-DOSE INFUSION RATES FOR PREVENTION OF CISPLATIN-INDUCED EMESIS [J].

SALLER, R ;

HELLENBRECHT, D ;

BRIEMANN, L ;

HELLSTERN, A ;

HESS, H ;

MITROU, P ;

HODGSON, M ;

ACHTERT, G ;

BROCKMANN, P ;

HAUSLEITER, HJ .

CLINICAL PHARMACOLOGY & THERAPEUTICS, 1985, 37 (01) :43-47

← 1 →